Publication

Video

Supplements and Featured Publications

BTK Inhibitors in B-Cell Lymphomas
Volume1
Issue 1

Dr. Kahl on Frontline BTK Inhibitor Selection in CLL

Author(s):

Brad Kahl, MD, discusses choosing between BTK inhibitors ibrutinib and acalabrutinib for frontline treatment of chronic lymphocytic leukemia.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses choosing between BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) for frontline treatment of chronic lymphocytic leukemia (CLL).

In May 2016, the FDA approved ibrutinib for the first-line treatment of patients with CLL based on the phase III RESONATE-2 data showing improved progression-free survival (PFS) with the agent over chlorambucil. Recently, a long-term update of the trial showed overall survival (OS) rates of 83% with ibrutinib versus 68% with chlorambucil after 60 months of follow-up for patients with CLL aged 65 years and older. Additionally, PFS estimates were 70% versus 12% after 5 years, respectively.

In November 2019, acalabrutinib was approved for adults with CLL or small lymphocytic leukemia based on the ELEVATE-TN trial for patients with previously untreated CLL and the ASCEND trial for relapsed/refractory disease. Though the data are less mature, it appears similar to that of ibrutinib, expresses Kahl.

Both agents suggest similar efficacy and are good BTK inhibitor options for CLL. There may be slightly increased toxicity with ibrutinib versus acalabrutinib. Finally, ibrutinib is a once daily regimen compared with the twice-daily schedule with acalabrutinib, concludes Kahl.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity